{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:59Z","timestamp":1786984319867,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ando.2025.101811","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:50:40Z","timestamp":1752565840000},"page":"101811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-utility analysis of second line acromegaly treatment in France"],"prefix":"10.1016","volume":"86","author":[{"given":"G\u00e9rald","family":"Raverot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Ferriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Beillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassila","family":"Aissani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Cabout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Ben Romdhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101811_bib0220","series-title":"Handbook of Clinical Neurology [Internet]","first-page":"197","article-title":"Chapter 14\u2013Acromegaly","author":"Chanson","year":"2014"},{"issue":"11","key":"10.1016\/j.ando.2025.101811_bib0225","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0230","first-page":"1","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primer"},{"issue":"10","key":"10.1016\/j.ando.2025.101811_bib0235","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ando.2025.101811_bib0245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EJE-21-0216","article-title":"Global epidemiology of acromegaly: a systematic review and meta-analysis","volume":"185","author":"Crisafulli","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.ando.2025.101811_bib0250","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ando.2025.101811_bib0255","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ando.2025.101811_bib0270","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ando.2023.08.003","article-title":"Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP)","volume":"84","author":"Brue","year":"2023","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101811_bib0275","doi-asserted-by":"crossref","first-page":"745843","DOI":"10.3389\/fendo.2021.745843","article-title":"Cost-utility of acromegaly pharmacological treatments in a french context","volume":"12","author":"Brue","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2025.101811_bib0280","series-title":"Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS","first-page":"118","year":"2020"},{"issue":"11","key":"10.1016\/j.ando.2025.101811_bib0285","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.ando.2025.101811_bib0290","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ando.2025.101811_bib0295","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2025.101811_bib0300","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.ando.2025.101811_bib0305","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ando.2025.101811_bib0310","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ando.2021.05.004","article-title":"Pegvisomant treatment in acromegaly in clinical practice: final results of the French ACROSTUDY (312 patients)","volume":"82","author":"Barraud","year":"2021","journal-title":"Ann Endocrinol"},{"issue":"2","key":"10.1016\/j.ando.2025.101811_bib0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ando.2025.101811_bib0320","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12020-015-0610-1","article-title":"Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly","volume":"50","author":"Diallo","year":"2015","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.ando.2025.101811_bib0325","doi-asserted-by":"crossref","first-page":"101898","DOI":"10.1016\/j.beem.2024.101898","article-title":"Efficacy and safety of radiosurgery in acromegaly","volume":"38","author":"Albano","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ando.2025.101811_bib0330","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.endonu.2016.05.010","article-title":"Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study","volume":"63","author":"Puig-Domingo","year":"2016","journal-title":"Endocrinol Nutr"},{"issue":"2","key":"10.1016\/j.ando.2025.101811_bib0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","year":"2019","journal-title":"Eur J Health Econ"},{"issue":"6","key":"10.1016\/j.ando.2025.101811_bib0340","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1210\/jc.2004-1565","article-title":"Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire","volume":"90","author":"Rowles","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ando.2025.101811_bib0345","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2016.05.018","article-title":"EQ-5D scores for diabetes-related comorbidities","volume":"19","author":"Sullivan","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.ando.2025.101811_bib0350","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","article-title":"Utilities and disutilities for attributes of injectable treatments for type 2 diabetes","volume":"12","author":"Boye","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12902-017-0166-6","article-title":"The association between biochemical control and cardiovascular risk factors in acromegaly","volume":"17","author":"Carmichael","year":"2017","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.ando.2025.101811_bib0360","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.acvd.2014.01.012","article-title":"Two-year outcome of patients after a first hospitalization for heart failure: a national observational study","volume":"107","author":"Tuppin","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10198-013-0554-4","article-title":"Cost of poor adherence to anti-hypertensive therapy in five European countries","volume":"16","author":"Mennini","year":"2015","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.ando.2025.101811_bib0370","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10198-017-0873-y","article-title":"The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach","volume":"19","author":"de Lagasnerie","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"10","key":"10.1016\/j.ando.2025.101811_bib0375","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","article-title":"Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women","volume":"20","author":"Bonadonna","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0380","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1472-6963-11-151","article-title":"Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France","volume":"11","author":"Cott\u00e9","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.ando.2025.101811_bib0385","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3111\/13696998.2015.1127816","article-title":"Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder","volume":"19","author":"Zhang","year":"2016","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.ando.2025.101811_bib0390","first-page":"1297","article-title":"Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists","volume":"31","author":"Guillemin","year":"2004","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eem.11.82","article-title":"Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment","volume":"7","author":"Davi","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1\u20132","key":"10.1016\/j.ando.2025.101811_bib0400","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0266462316000088","article-title":"Cost-effectiveness of treatments for mild-to-moderate obstructive sleep apnea in FRANCE","volume":"32","author":"Poulli\u00e9","year":"2016","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0405","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","article-title":"Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-\u03b12a compared with sunitinib","volume":"102","author":"Mickisch","year":"2010","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ando.2025.101811_bib0410","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11102-018-0908-0","article-title":"Cost-effectiveness of acromegaly treatments: a systematic review","volume":"21","author":"Leonart","year":"2018","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ando.2025.101811_bib0415","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000507890","article-title":"Pharmacological acromegaly treatment: cost-utility and value of information analysis","volume":"111","author":"Leonart","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2025.101811_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7365\/JHPOR.2018.2.3","article-title":"Cost-utility analysis and budget impact analysis of pegvisomant for the treatment of adult patients with acromegaly in Poland","volume":"2","author":"Borowiack","year":"2019","journal-title":"J Health Policy Outcomes Res"},{"issue":"1","key":"10.1016\/j.ando.2025.101811_bib0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737167.2019.1610396","article-title":"Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain","volume":"20","author":"Peral","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ando.2025.101811_bib0430","doi-asserted-by":"crossref","first-page":"1573721","DOI":"10.3389\/fendo.2025.1573721","article-title":"Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study","volume":"16","author":"Venegas Moreno","year":"2025","journal-title":"Front Endocrinol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T01:44:50Z","timestamp":1764985490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0003426625001301"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101811","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility analysis of second line acromegaly treatment in France","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101811"}}